CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $244.66M, lower than 95% of all stocks globally
- PositionPrice-to-book is 0.67×, lower than 95% of its Biotechnology peers (median 2.97×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.26%
Annual Rate
HKD 0.07Paid annual
Payout Ratio
10.0%Sustainable
Last Ex-Dividend
Jun 17, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.92BHKD244.66M · vs all stocks (USD)
Trailing P/E
8.03xvs Biotechnology peers
Revenue (TTM)
1.52BCNY193.76M · vs all stocks (USD)
Profit Margin
10.60%vs Biotechnology peers
52-Week Change
-65.93%vs all stocks
Market Capitalization
1.92BHKD244.66M · vs all stocks (USD)
Enterprise Value
878.57MHKD112.01M · vs all stocks (USD)
Trailing P/E
8.03xvs Biotechnology peers
Price to Sales (TTM)
0.9602xvs Biotechnology peers
Price to Book (MRQ)
0.6678xvs Biotechnology peers
Enterprise to Revenue
0.5780xvs Biotechnology peers
Enterprise to EBITDA
4.24xvs Biotechnology peers
Profit Margin
10.60%vs Biotechnology peers
Operating Margin
7.52%vs Biotechnology peers
Return on Assets (TTM)
4.37%vs Biotechnology peers
Return on Equity (TTM)
8.74%vs Biotechnology peers
Revenue (TTM)
1.52BCNY193.76M · vs all stocks (USD)
Revenue per Share (TTM)
5.32CNYUpdated Aug 19, 2026Quarterly Revenue Growth
0.10%vs Biotechnology peers
Gross Profit (TTM)
1.23BCNY156.35M · vs all stocks (USD)
EBITDA (TTM)
211.76MCNY27.00M · vs all stocks (USD)
Net Income (TTM)
161.03MCNY20.53M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
45.00%vs Biotechnology peers
Operating Cash Flow (TTM)
296.50MCNY37.80M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
97.56MCNY12.44M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0655HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
1.26%vs all stocks
Payout Ratio
9.95%vs Biotechnology peers
Revenue
1.31BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
252.24MCNYFY2025 · Dec 31, 2025Gross Profit
1.05BCNYFY2025 · Dec 31, 2025Operating Income
159.53MCNY23.66M · vs all stocks (USD)
Pre-tax Income
161.52MCNYFY2025 · Dec 31, 2025Income Tax Expense
23.12MCNYFY2025 · Dec 31, 2025Net Income
138.41MCNYFY2025 · Dec 31, 2025EBIT
167.19MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
211.76MCNYFY2025 · Dec 31, 2025Research & Development
123.66MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
547.89MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.52MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
5.66MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
195.59MCNYFY2025 · Dec 31, 2025Free Cash Flow
146.08MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
348.67MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
161.52MCNYFY2025 · Dec 31, 2025Stock-based Compensation
5.55MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-4.86MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
41.35MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.98MCNYFY2025 · Dec 31, 2025Capital Expenditures
-49.51MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-55.06MCNYFY2025 · Dec 31, 2025Purchase of Investments
-300.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-349.51MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
114.90MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-132.10MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-13.73MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-30.93MCNYFY2025 · Dec 31, 2025Shares Outstanding
245.40MSharesUpdated Aug 19, 2026Float Shares
66.22MSharesUpdated Aug 19, 2026% Held by Insiders
84.80%vs all stocks
% Held by Institutions
0.03%vs all stocks
Total Cash (MRQ)
831.26MCNY105.98M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.91CNYUpdated Aug 19, 2026Total Debt (MRQ)
188.04MCNY23.97M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0981xvs Biotechnology peers
Current Ratio (MRQ)
4.46xvs Biotechnology peers
Book Value per Share (MRQ)
7.82CNYUpdated Aug 19, 2026Total Assets
2.12BCNY314.10M · vs all stocks (USD)
Total Current Assets
1.48BCNYFY2025 · Dec 31, 2025Total Liabilities
469.74MCNYFY2025 · Dec 31, 2025Total Non-current Assets
634.81MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
137.35MCNYFY2025 · Dec 31, 2025Total Current Liabilities
332.39MCNYFY2025 · Dec 31, 2025Cash
348.67MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
348.67MCNYFY2025 · Dec 31, 2025Other Short-term Investments
365.79MCNYFY2025 · Dec 31, 2025Accounts Receivable
571.06MCNYFY2025 · Dec 31, 2025Inventory
149.75MCNYFY2025 · Dec 31, 2025Accounts Payable
48.38MCNYFY2025 · Dec 31, 2025Short-term Debt
48.94MCNYFY2025 · Dec 31, 2025Long-term Debt
112.68MCNYFY2025 · Dec 31, 2025Common Stock (Book)
245.40MCNYFY2025 · Dec 31, 2025Retained Earnings
246.52MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.65BCNY244.43M · vs all stocks (USD)
52-Week Low
4.60HKDUpdated Aug 19, 202652-Week High
15.99HKDUpdated Aug 19, 202652-Week Change
-65.93%vs all stocks
50-Day MA
5.73HKDUpdated Aug 19, 2026200-Day MA
7.33HKDUpdated Aug 19, 2026Avg 10-Day Volume
39.28KSharesUpdated Aug 19, 2026Avg 30-Day Volume
75.63KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.6500CNYUpdated Aug 19, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.67×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.67Industry median: 2.97Industry P5: 1.03Peers compared: 261
Financial Health
Altman Z-Score 3.79: safe zoneNotable
Altman Z-Score: 3.79
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $244.66M, lower than 95% of all stocks globallySignificant
Market cap (USD): 244,655,683.354Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Heartseed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fulcrum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Greenwich LifeSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shenqi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immunotech Biopharm Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Jiaying Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Colgate-Palmolive (India) Ltd.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedIndustry-Benchmarked Return on Capital ElevatedMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
VT Co., Ltd.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedIndustry-Benchmarked Return on Capital ElevatedMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Kansai Nerolac Paints Ltd.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedIndustry-Benchmarked Return on Capital ElevatedMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities